.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
Chronic Health concentrated 70.53% of May 2026 sales in Topical while Tincture & Sublingual held 29.47%, with Topical down 27.99% year over year and 12.44% month over month, and Tincture & Sublingual down 52.77% year over year and 17.27% month over month. Despite an average price rising 6.02% and a category-average price gap between Topical at $24.09 and Tincture & Sublingual at $13.86, overall brand sales fell 37.64% year over year and 19.01% versus the 24‑month baseline, indicating that mix skew toward Topical partly buffered but did not offset heavier declines in Tincture & Sublingual; the pattern implies a reliance on a shrinking core where price lift is insufficient to counter volume contraction.
Holding rank 2 in Topical within Arizona while Topical’s share is 70.53% positions Chronic Health as a category specialist whose placement depends on sustaining Topical velocity even as that category contracted 12.44% month over month. With Tincture & Sublingual down 17.27% month over month and 52.77% year over year against a 29.47% share, the brand’s exposure to a faster-declining secondary category elevates risk concentration; the implication is to defend the Topical rank through targeted price-pack architecture around a 6.02% price increase while reallocating attention from Tincture & Sublingual where elasticity likely amplifies volume loss.
Competitive Landscape
Chronic Health sits at rank #2 in AZ Topical in May 2026, improving 1 position YoY from #3, and holding flat versus three months ago at #2, while its historical peak was #1 in March 2025; meanwhile, Drip Oils + Extracts moved from #2 YoY to #1 currently with a 38.3% YoY sales increase, and Gramz advanced from #7 YoY to #3 with 123.2% YoY growth, contrasting with Tru Infusion holding at #4 YoY but posting a 14.7% YoY decline; this combination of a 1-rank YoY climb for Chronic Health and accelerating gains by immediate neighbors implies the brand must convert stability at #2 into share-taking moves if it intends to reclaim the #1 position last reached in March 2025.
Notable Products
CBD/THC 1:1 Glycerin Tincture (100mg CBD, 100mg THC, 1oz) posted the steepest decline at -24.53% month over month in May 2026 while sitting at rank 4, and CBD/THC 1:1 Pain Relief Ointment (175mg CBD, 175mg THC, 2oz) fell -23.64% at rank 3. The CBD/THC 1:1 Sleep Well Tincture (100mg CBD, 100mg THC, 1oz) dropped -21.69% and ranked 2, contrasting with the category leader Indica THC Glycerin Tincture (100mg THC, 1oz) at rank 1 with a -1.32% dip and $4,321 in May 2026 sales. Four of the top ten are Topical SKUs and three are Tincture & Sublingual SKUs, and with only CBD High Ointment (350mg CBD, 2oz) inching up +1.70% at rank 9, the pattern points to pressure on mixed CBD/THC formulas and a tilt toward simpler THC-led offerings to defend share.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
